纵向分析循环肿瘤DNA检测EGFR突变阳性晚期非小细胞肺癌治疗期间疾病进展:来自FLAURA和AURA3试验的数据
该回顾性探索性分析基于FLAURA和AURA3两项3期试验,评估纵向EGFR突变循环肿瘤DNA检测能否在影像学进展前发现疾病进展。结果显示ctDNA进展先于或同步于RECIST定义进展的比例在FLAURA为64%(93/146)、AURA3为56%(82/146),中位提前时间分别为3.4和2.6个月(FLAURA两臂)及2.8和1.5个月(AURA3两臂),提示纵向ctDNA监测可能先于影像学发现进展。
要点
- ctDNA进展先于或同步于RECIST进展的比例:FLAURA 64%(93/146),AURA3 56%(82/146)。
- FLAURA中位ctDNA进展至RECIST进展时间:奥希替尼组3.4个月,对照EGFR-TKI组2.6个月。
- AURA3中位ctDNA进展至RECIST进展时间:奥希替尼组2.8个月,化疗组1.5个月。
核心结论
- 在接受EGFR-TKI或化疗且有ctDNA数据及RECIST定义进展的EGFR突变阳性晚期NSCLC患者中,约60%的病例ctDNA进展先于或同步于RECIST定义进展。
- 纵向ctDNA监测可能先于影像学进展发现疾病进展。
研究设计与样本
- 回顾性、探索性ctDNA分析,基于两项3期试验(FLAURA,NCT02296125;AURA3,NCT02151981)。
- 纳入初治(FLAURA)或EGFR-TKI经治(AURA3)的EGFR突变晚期NSCLC患者,且出现研究期间RECIST定义进展,并有基线ctDNA结果及第3周期第1天后EGFR突变ctDNA监测数据。
- 患者接受奥希替尼对比对照EGFR-TKI(FLAURA)或化疗(AURA3)。
主要发现
- ctDNA进展先于或同步于RECIST定义进展:FLAURA 93/146例(64%),AURA3 82/146例(56%)。
- ctDNA进展至RECIST定义进展的中位时间(月):FLAURA奥希替尼组3.4,对照EGFR-TKI组2.6;AURA3奥希替尼组2.8,化疗组1.5。
- FLAURA中ctDNA进展至首次后续治疗的中位时间(月):奥希替尼组(n=51)6.0,对照EGFR-TKI组(n=70)4.7。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: EGFR tyrosine kinase inhibitor (EGFR-TKI)-sensitizing and -resistance mutations may be detected in plasma through circulating tumor DNA (ctDNA). Circulating tumor DNA level changes reflect alterations in tumor burden and could be a dynamic indicator of treatment effect. This analysis aimed to determine whether longitudinal EGFR-mutation ctDNA testing could detect progressive disease (PD) before radiologic detection. METHODS: This was a retrospective, exploratory ctDNA analysis in two phase 3 trials (FLAURA, NCT02296125; AURA3, NCT02151981). Patients had treatment-naïve (FLAURA) or EGFR-TKI pre-treated (AURA3) advanced NSCLC with EGFR mutations and on-study PD (RECIST [Response Evaluation Criteria in Solid Tumors]), with a baseline ctDNA result and EGFR-mutation ctDNA monitoring beyond Cycle 3 Day 1. Patients received osimertinib versus comparator EGFR-TKIs (FLAURA) or chemotherapy (AURA3). Outcomes included time from ctDNA PD to RECIST PD and the first subsequent treatment (FLAURA only). RESULTS: Circulating tumor DNA PD preceded or co-occurred with RECIST-defined PD in 93 out of 146 patients (64%) in FLAURA and 82 out of 146 patients (56%) in AURA3. Median time from ctDNA PD to RECIST-defined PD (mo) was 3.4 and 2.6 in the osimertinib and comparator EGFR-TKI arms (FLAURA) and 2.8 and 1.5 in the osimertinib and chemotherapy arms (AURA3). In FLAURA, the median time from ctDNA PD to the first subsequent treatment (mo) was 6.0 and 4.7 in the osimertinib (n = 51) and comparator EGFR-TKI arms (n = 70). CONCLUSIONS: Among patients with EGFR mutation-positive advanced NSCLC receiving EGFR-TKI or chemotherapy with ctDNA data and RECIST-defined PD, ctDNA PD preceded/co-occurred with RECIST-defined PD in approximately 60% of cases. Longitudinal ctDNA monitoring may detect PD before radiologic PD.
引用
- Gray JE, Markovets A, Reungwetwattana T, et al. Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3. J Thorac Oncol. 2024. PMID: 39029876. doi:10.1016/j.jtho.2024.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。